NASDAQ:ORPH Orphazyme A/S (ORPH) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free ORPH Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.57▼$2.2152-Week Range N/AVolume941,400 shsAverage Volume1.37 million shsMarket Capitalization$30.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Orphazyme A/S alerts: Email Address Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. About Orphazyme A/S Stock (NASDAQ:ORPH)Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.Read More Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. ORPH Stock News HeadlinesMarch 18, 2024 | msn.comUnderstanding what causes trastuzumab's cardiotoxicityMarch 16, 2024 | msn.comHow a brash, red-haired orphan from P.E.I. continues to be a worldwide sensationMarch 28, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.March 14, 2024 | msn.comSindica - A Novel, Patented Post-emergence Herbicide for Sugarcane from AtulMarch 12, 2024 | msn.comSharing a Drink With Orphaned Opossum BabiesMarch 12, 2024 | msn.comZevra adds bull at William Blair despite delay in arimoclomol decisionMarch 11, 2024 | msn.com'Why haven't they shown us the original photo?' Anti-monarchist FUMES over Kate's apology - ‘Doesn't explain anything’March 10, 2024 | nytimes.comA.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the MarketMarch 28, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.March 5, 2024 | msn.comAlnylam’s experimental drug for high blood pressure yields encouraging resultsMarch 4, 2024 | marketwatch.comFDA Extends Review of Zevra's Arimoclomol by Three MonthsFebruary 23, 2024 | msn.comLadybug scents offer a more ecologically friendly way to protect cropsFebruary 23, 2024 | msn.comGen Alpha have a say on which names they consider to be 'old'February 23, 2024 | yahoo.comOne Piece: Is S-Hawk the Strongest Seraphim in the Series?February 22, 2024 | msn.comWhat Is The History Of Phenylketonuria? A Review By DoctorsJanuary 31, 2024 | msn.comNew Horizons in Chemical Biology: A Novel Approach to Synthesize Dibenzothiophene S-OxidesJanuary 31, 2024 | msn.comChemical biology: A novel approach to synthesize dibenzothiophene s-oxidesDecember 5, 2023 | markets.businessinsider.comLevi & Korsinsky, LLP Notifies Shareholders of Orphazyme (ORPH) an Upcoming Claims Deadline in a Class Action SettlementNovember 4, 2023 | msn.comWhat is Suboxone? Web sleuths speculate possible role of drug in Matthew Perry's hot tub death amid delayed toxicology reportNovember 3, 2023 | msn.comMonkeypox ‘circulating for five years’ before 2022’s global health emergencyOctober 29, 2023 | msn.comMatthew Perry's autopsy has been completed but results are pending a toxicology reportAugust 24, 2023 | msn.comOne Piece Reveals The Seraphim's Surprising WeaknessAugust 23, 2023 | msn.comWhat’s Going Around: poison oakAugust 21, 2023 | nypost.comAlpha-gal syndrome: LI county a hot spot for tick-borne meat allergyAugust 18, 2023 | msn.comUS FDA approves higher dose of Regeneron's eye disease drug EyleaAugust 17, 2023 | investing.comOrphazyme A/S (ORPHA)August 8, 2023 | yahoo.comRaven-Symoné suffered a seizure after having breast reductions, liposuction before turning 18See More Headlines Receive ORPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orphazyme A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ORPH CUSIPN/A CIK1764791 Webwww.orphazyme.com Phone45-2898-9055FaxN/AEmployees141Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.14 Current Ratio1.80 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.74 per share Price / BookN/AMiscellaneous Outstanding Shares35,312,000Free FloatN/AMarket Cap$30.72 million OptionableNot Optionable Beta1.68 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Anders Fink Vadsholt M.B.A. (Age 52)M.Sc., MBA, Chief Financial Officer Comp: $924.24kMr. Christophe Bourdon M.B.A. (Age 51)Chief Exec. Officer Dr. Thomas Kirkegaard Jensen Ph.D. (Age 44)Co-Founder & Chief Scientific Officer Ms. Molly Carey PoarchHead of Global CommunicationsDr. Thomas Blaettler (Age 54)Chief Medical Officer Ms. Molly Painter (Age 45)Pres of Orphazyme US, Inc. More ExecutivesKey CompetitorsAlaunos TherapeuticsNASDAQ:TCRTAptorum GroupNASDAQ:APMAcasti PharmaNASDAQ:ACSTSpruce BiosciencesNASDAQ:SPRBAcurx PharmaceuticalsNASDAQ:ACXPView All Competitors ORPH Stock Analysis - Frequently Asked Questions When did Orphazyme A/S IPO? Orphazyme A/S (ORPH) raised $100 million in an IPO on Tuesday, September 29th 2020. The company issued 7,600,000 shares at a price of $13.13 per share. BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO and Danske Markets was co-manager. This page (NASDAQ:ORPH) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orphazyme A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.